{"id":"NCT00574795","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","briefTitle":"Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants","officialTitle":"A Phase 3, Open-Label Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2008-08","completion":"2008-08","firstPosted":"2007-12-17","resultsPosted":"2012-08-08","lastUpdate":"2012-08-08"},"enrollment":193,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Vaccines, Pneumococcal Conjugate Vaccine"],"interventions":[{"type":"BIOLOGICAL","name":"13vPnC","otherNames":[]}],"arms":[],"summary":"The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine (13vPnC) in infants of Japanese descent.","primaryOutcome":{"measure":"Percentage of Participants Achieving Antibody Level ≥ 0.35 μg/mL in the 13vPnC Group After the 3-Dose Infant Series","timeFrame":"one month after 3-dose infant series (at 7 months of age)","effectByArm":[{"arm":"13vPnC After Infant Series","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":24,"countries":["Japan"]},"refs":{"pmids":["23538524"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":193},"commonTop":["Injection site erythema","Erythema (Any)","Injection site swelling","Erythema (Mild)","Pyrexia"]}}